NextFin News - Jim Cramer’s Charitable Trust has executed a strategic pivot within the pharmaceutical sector, liquidating its entire remaining stake in Bristol Myers Squibb (BMY) to initiate a new position in Johnson & Johnson (JNJ). The move, announced Wednesday, saw the Trust sell 1,100 shares of Bristol Myers at approximately $58.94 while simultaneously purchasing 150 shares of Johnson & Johnson at $237.65. The trade effectively swaps a company facing looming patent cliffs and clinical trial setbacks for a diversified giant with a more robust oncology and medical technology footprint.
Jeff Marks, Director of Portfolio Management for the Charitable Trust, noted that the decision was driven by a desire to lock in a 3.5% gain on Bristol Myers rather than risk a reversal. Marks, who typically oversees the Trust’s long-term growth-and-income strategy, has recently favored companies with "commercial excellence" over those dependent on binary clinical trial outcomes. While Bristol Myers shares have rallied 30% over the last six months as tariff fears subsided, the stock’s longer-term performance has lagged significantly behind Johnson & Johnson, which has surged 58% over the past year.
The divergence in performance reflects the differing fundamental health of the two drugmakers. Bristol Myers has struggled with the failure of its schizophrenia drug, Cobenfy, in a late-stage trial for adjunctive treatment, a blow to a pipeline intended to offset upcoming revenue losses from expiring patents. In contrast, Johnson & Johnson reported $94 billion in sales for 2025, bolstered by double-digit growth across 13 key brands. Its oncology franchise alone generated $25 billion last year, with management projecting that figure to double to $50 billion by 2030, led by heavyweights like Darzalex and Carvykti.
Beyond pharmaceuticals, Johnson & Johnson’s MedTech division provides a defensive cushion that Bristol Myers lacks. The unit grew revenue by 5.4% in 2025, focusing on high-margin cardiovascular and surgical segments. Furthermore, Johnson & Johnson has directly challenged Bristol Myers in the immunology space. The recent FDA approval of Icotyde, the first oral IL-23 inhibitor for plaque psoriasis, positions J&J to seize market share from Bristol’s Sotyktu. Head-to-head trials conducted last fall showed Icotyde delivered superior skin clearance compared to the Bristol Myers alternative.
However, the pharmaceutical sector remains fraught with regulatory and competitive risks that could temper this optimism. While the Trust is betting on J&J’s scale, the company still faces ongoing litigation related to its talc products, a multi-billion dollar liability that continues to hang over its valuation. Some analysts on the sell-side remain cautious, suggesting that the premium price for J&J shares—now trading near all-time highs—leaves little room for error if its MedTech integration or new drug launches underperform. The Trust’s move represents a specific tactical shift toward quality and diversification rather than a broad consensus on the sector’s immediate direction.
The irony of the swap is not lost on market observers: the two companies remain partners on Milvexian, a promising stroke prevention drug currently in trials. While a success for Milvexian would provide a larger relative boost to the smaller Bristol Myers, the Charitable Trust has signaled that it no longer wishes to wait for such "binary events." By moving into Johnson & Johnson, the portfolio gains exposure to a broader array of revenue streams, from robotic surgery to next-generation cancer therapies, effectively trading volatility for the steady compounding of a healthcare conglomerate.
Explore more exclusive insights at nextfin.ai.
